Results 131 to 140 of about 199,597 (317)

Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden [PDF]

, 2020
Joanne Stockton, Louise Tee, Celina Whalley, Jonathan James, Mark Dilworth, Rachel Wheat, Thomas Nieto, Ian Geh, Andrew D. Beggs   +8 more
openalex   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Tumor Mutation Burden [PDF]

, 2020
openaire   +1 more source

Low tumor mutational burden and immunotherapy in gliomas

Trends in Cancer, 2022
Brown, Michael C., Ashley, David M., Khasraw, Mustafa   +2 more
openaire   +2 more sources

Tumor Mutation Burden in lung cancer

Annals of Oncology, 2019
Abstract The clinical success of PD-1 pathway-targeted immunotherapy in a subset of lung cancer patients is imperfectly predicted by PD-L1 expression alone. Very unlike the targeting of activating driver mutations, PD-L1 represents a continuous variable that is semi-quantitatively assessed currently by immunotherapy and only relatively enriches for ...
openaire   +1 more source

Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors

, 2023
Jitka Fučíková, Michal Hensler, Lenka Kašíková, Tereza Láníčková, Josef Pasulka, Jana Raková, Jana Drozenová, Tessa Fredriksen, Marek Hraska, Tereza Hrnčiarová, Klára Sochorová, Daniela Rožková, Luděk Sojka, Pavel Dundr, Ján Laco, Tomáš Brtnický, Ivan Práznovec, Michael J. Halaška, Lukáš Rob, Aleš Ryška, An Coosemans, Ignace Vergote, David Cibula, Jiřina Bartůňková, Jérôme Galon, Lorenzo Galluzzi, Radek Špíšek   +26 more
openalex   +1 more source

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups [PDF]

, 2021
Yan W. Asmann, Kaushal Parikh, P. Leif Bergsagel, Haidong Dong, Alex A. Adjei, Mitesh J. Borad, Aaron S. Mansfield   +6 more
openalex   +1 more source

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

Scientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby, Ernest Bognar, Laura Stanbery, Casey Nagel, Gladice Wallraven, Aman Pruthi, Nicholas Bild, Ericca Stamper, Donald Rao, Adam Walter, John Nemunaitis   +10 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Mutational burden of neurons [PDF]

Nature Methods, 2016
openaire   +1 more source